Literature DB >> 23357500

The DNA methylomes of serous borderline tumors reveal subgroups with malignant- or benign-like profiles.

Constanze Zeller1, Wei Dai, Edward Curry, Afshan Siddiq, Andrew Walley, Nahal Masrour, Isidora Kitsou-Mylona, Gail Anderson, Sadaf Ghaem-Maghami, Robert Brown, Mona El-Bahrawy.   

Abstract

Serous borderline tumors (SBOTs) are a challenging group of ovarian tumors positioned between benign and malignant disease. We have profiled the DNA methylomes of 12 low-grade serous carcinomas (LGSCs), 19 SBOTs, and 16 benign serous tumors (BSTs) across 27,578 CpG sites to further characterize the epigenomic relationship between these subtypes of ovarian tumors. Unsupervised hierarchical clustering of DNA methylation levels showed that LGSCs differ distinctly from BSTs, but not from SBOTs. Gene ontology analysis of genes showing differential methylation at linked CpG sites between LGSCs and BSTs revealed significant enrichment of gene groups associated with cell adhesion, cell-cell signaling, and the extracellular region, consistent with a more invasive phenotype of LGSCs compared with BSTs. Consensus clustering highlighted differences between SBOT methylomes and returned subgroups with malignant- or benign-like methylation profiles. Furthermore, a two-loci DNA methylation signature can distinguish between these SBOT subgroups with benign- and malignant-like methylation characteristics. Our findings indicate striking similarities between SBOT and LGSC methylomes, supporting a common origin and the view that LGSC may arise from SBOT. A subgroup of SBOTs can be classified into tumors with a benign- or a malignant-like methylation profile that may help in identifying tumors more likely to progress into LGSCs.
Copyright © 2013 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23357500     DOI: 10.1016/j.ajpath.2012.11.040

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  6 in total

Review 1.  DNA methylation changes in epithelial ovarian cancer histotypes.

Authors:  Madalene A Earp; Julie M Cunningham
Journal:  Genomics       Date:  2015-09-10       Impact factor: 5.736

2.  Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas.

Authors:  Alicia A Tone; Melissa K McConechy; Winnie Yang; Jiarui Ding; Stephen Yip; Esther Kong; Kwong-Kwok Wong; David M Gershenson; Helen Mackay; Sohrab Shah; Blake Gilks; Anna V Tinker; Blaise Clarke; Jessica N McAlpine; David Huntsman
Journal:  BMC Cancer       Date:  2014-12-18       Impact factor: 4.430

3.  Genome-wide promoter methylome of small renal masses.

Authors:  Ilsiya Ibragimova; Michael J Slifker; Marie E Maradeo; Gowrishankar Banumathy; Essel Dulaimi; Robert G Uzzo; Paul Cairns
Journal:  PLoS One       Date:  2013-10-24       Impact factor: 3.240

4.  MRI appearance of ovarian serous borderline tumors of the micropapillary type compared to that of typical ovarian serous borderline tumors: radiologic-pathologic correlation.

Authors:  Go Nakai; Takashi Yamada; Kazuhiro Yamamoto; Yoshinobu Hirose; Masahide Ohmichi; Yoshifumi Narumi
Journal:  J Ovarian Res       Date:  2018-01-10       Impact factor: 4.234

5.  Klotho promoter methylation status and its prognostic value in ovarian cancer.

Authors:  Maryam H Al-Zahrani; Fatimah M Yahya; Mourad Assidi; Ashraf Dallol; Abdelbaset Buhmeida
Journal:  Mol Clin Oncol       Date:  2021-07-03

6.  Association of promoter methylation of VGF and PGP9.5 with ovarian cancer progression.

Authors:  Mariana Brait; Leonel Maldonado; Maartje G Noordhuis; Maartje Noordhuis; Shahnaz Begum; Myriam Loyo; Maria Luana Poeta; Alvaro Barbosa; Vito M Fazio; Roberto Angioli; Carla Rabitti; Luigi Marchionni; Pauline de Graeff; Ate G J van der Zee; G Bea A Wisman; David Sidransky; Mohammad O Hoque
Journal:  PLoS One       Date:  2013-09-27       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.